Saehyeon Kim, Kazuteru Murakoshi, Ken Goda, Paniz Parvar, Zeyad Abdelaziz
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
No local reference links have been materialized yet.
No local citing links have been materialized yet.
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA guideline for the management of patients with chronic coronary disease
10.1016/j.jacc.2023.04.003 · 2023
Global, regional, and national burden of cardiovascular diseases and risk factors in 204 countries and territories, 1990-2023
10.1016/j.jacc.2025.08.015 · 2025
Global, regional and national burden of ischemic heart disease and its attributable risk factors from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021
10.1186/s12872-025-05022-x · 2025
Diagnosis and management of stable angina
10.1001/jama.2021.1527 · 2021
Management and clinical outcome of stable coronary artery disease in Austria
10.1007/s00508-017-1248-1 · 2017
New-onset atrial fibrillation and chronic coronary syndrome in the CLARIFY registry
10.1093/eurheartj/ehad556 · 2023
Prevalence and clinical characteristics of atrial fibrillation in hospitalized patients with coronary artery disease and hypertension: a cross-sectional study from 2008 to 2018
10.1097/cm9.0000000000002471 · 2023
Antiplatelet agents for the treatment and prevention of coronary atherothrombosis
10.1016/j.jacc.2017.08.037 · 2017
State of the art: evaluation and medical management of nonobstructive coronary artery disease in patients with chest pain: a scientific statement from the American Heart Association
Confidence 0%
10.1161/cir.0000000000001394 · 2025
Atrial fibrillation
10.1016/j.jacc.2020.02.025 · 2020
Primary and secondary prevention of ischemic stroke and cerebral hemorrhage
10.1016/j.jacc.2019.12.072 · 2020
Antithrombotic therapy for primary and secondary prevention of ischemic stroke
10.1016/j.jacc.2023.07.025 · 2023
2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation
10.1016/j.jacc.2023.08.017 · 2024
Atrial fibrillation
10.1056/nejmcp2023658 · 2021
Antithrombotic therapy for VTE disease
10.1016/j.chest.2021.07.055 · 2021
Rivaroxaban with or without aspirin in stable cardiovascular disease
10.1056/nejmoa1709118 · 2017
Edoxaban antithrombotic therapy for atrial fibrillation and stable coronary artery disease
10.1056/nejmoa2407362 · 2024
Edoxaban monotherapy in nonvalvular atrial fibrillation patients with coronary artery disease
10.1155/2022/5905022 · 2022
Therapy for atrial fibrillation in patients with drug-eluting stents
10.1056/nejmoa2512091 · 2026
Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation
10.1056/nejmoa2507532 · 2025
Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation
10.1161/circulationaha.118.036768 · 2019
Antithrombotic therapy for atrial fibrillation with stable coronary disease
10.1056/nejmoa1904143 · 2019
Oral anticoagulation with versus without antiplatelet therapy in patients with stable coronary artery disease and an indication for anticoagulation: a meta-analysis with trial sequential analysis
10.1080/14656566.2025.2610371 · 2025
Antithrombotic monotherapy or combination therapy for atrial fibrillation in stable coronary artery disease: a meta-analysis of randomized trials
10.1161/jaha.125.041422 · 2025
Anticoagulation and antiplatelet therapy for atrial fibrillation and stable coronary disease
10.1016/j.jacc.2024.12.030 · 2025
Anticoagulation alone or with antiaggregation in patients with coronary artery disease
10.1016/j.jacc.2026.01.026 · 2026
Long-term antithrombotic therapy for patients with atrial fibrillation and stable coronary artery disease
10.1002/14651858.cd014819 · 2021
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
10.1093/eurheartj/ehae176 · 2024
2024 ESC Guidelines for the management of chronic coronary syndromes
10.1093/eurheartj/ehae177 · 2024
Stroke prevention in atrial fibrillation
10.1016/j.jacasi.2022.05.005 · 2022
The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease
10.1055/s-0040-1718729 · 2020
Standardized outcome measurement for patients with coronary artery disease: consensus from the International Consortium for Health Outcomes Measurement (ICHOM)
10.1161/jaha.115.001767 · 2015
Definition of major bleeding: prognostic classification
10.1111/jth.15048 · 2020
Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH
10.1111/jth.13140 · 2015
Unresolved referenced work
Kept as external metadata until matched
PRISMA-S: an extension to the PRISMA statement for reporting literature searches in systematic reviews
10.5195/jmla.2021.962 · 2021
Unresolved referenced work
Kept as external metadata until matched
Rayyan – a web and mobile app for systematic reviews
10.1186/s13643-016-0384-4 · 2016
Unresolved referenced work
Kept as external metadata until matched
PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews
10.1136/bmj.n160 · 2021
Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline
10.1136/bmj.l6890 · doi-reference
A comparison of heterogeneity variance estimators in simulated random-effects meta-analyses
10.1002/jrsm.1316 · doi-reference
Practical methods for incorporating summary time-to-event data into meta-analysis
10.1186/1745-6215-8-16 · doi-reference
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews
10.1136/bmj.n71 · doi-reference
